Dechert Report Finds Life Sciences Companies Remain Popular Targets of U.S. Class Action Securities Lawsuits
February 12, 2019
NACD Director’s Daily
Dechert LLP has released its annual Developments in U.S. Securities Fraud Class Actions Against Life Sciences Companies report. The findings show that, although 2018 saw a slight decrease in class action securities litigation on the whole, life sciences companies were, once again, popular targets of such lawsuits, with no indication that the filings of securities claims against these companies will slow down any time soon. Prudent life sciences companies should continue to take heed of the results of last year's decisions and filings, many of which are highlighted in this report, to ensure that they are aware of the recent developments in the law as well as filing trends.
Read "Dechert Survey: Developments in U.S. Securities Fraud Class Actions Against Life Sciences Companies"
Related Professionals
